Phase II Clofarabine and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia
Stopped early · Phase 2
Conditions studied: Acute Myeloid Leukemia
In brief
The combination of clofarabine and cytarabine is an effective and reasonably well-tolerated treatment regimen in patients with either relapsed/refractory or newly diagnosed AML. For this prospective study, we propose the use of clofarabine and cytarabine for second course induction therapy for patients with persistent AML after treatment with an anthracycline and cytarabine.
Key facts
- Study ID
- NCT01960387
- Run by
- University of Pittsburgh
- People needed
- 2
- Starts
- 2013-10-01
- Expected to finish
- 2015-03-01
- Last updated by the study team
- 2016-08-02
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients with newly diagnosed AML based on the World Health Organization classification who have persistent disease after their first course treatment with an anthracycline and cytarabine
- Able to understand and have the ability to provide written informed consent
- Patients over 18 years of age
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
- Left ventricular ejection fraction (LVEF) ≥ 50%
- Negative urine pregnancy test for all females
- All subjects must agree to use an effective method of contraception while receiving the study drugs
You may not qualify if…
- Diagnosis of acute promyelocytic leukemia
- Relapsed AML
- Prior use of clofarabine
- Previous allogeneic or autologous hematopoietic cell transplantation
- Impaired liver function (serum total bilirubin > 2.0 mg/dL, alanine aminotransferase and aspartate aminotransferase ≥ 4 x the upper limit of normal)
- Impaired renal function (serum creatinine ≥ 2.0 mg/dL)
- Uncontrolled or life-threatening infection that is not responding to antimicrobial therapy
- History of a psychiatric disorder which may compromise compliance with the protocol or which does not allow for appropriate informed consent
- Concurrent active malignancy; exceptions include patients who have been disease free for 5 years, patients with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma, or patients with another malignancy that is indolent or definitively treated
- Evidence of severe or uncontrolled systemic diseases (e.g., unstable or uncompensated respiratory or cardiac disease)
Where it is running
- UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.